<DOC>
	<DOCNO>NCT01274273</DOCNO>
	<brief_summary>The purpose study determine whether interleukin-2 , interferon-alpha combination bevacizumab effective treatment metastatic renal cell carcinoma ( mRCC ) .</brief_summary>
	<brief_title>Study Interleukin-2 , Interferon-alpha Bevacizumab Metastatic Kidney Cancer</brief_title>
	<detailed_description>Bevacizumab monotherapy effect metastatic renal cell carcinoma ( mRCC ) . Bevacizumab combination interferon-alfa ( IFN-α ) significant efficacy mRCC approve EMA FDA . The present study ass whether combination Interleukin-2 ( IL-2 ) IFN-α bevacizumab may add efficacy patient mRCC tolerable safety profile .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Patient must willing able comply protocol . 3 . Age ≥ 18 year . 4 . Histologic og cytologic biopsy prove locally advanced metastatic renal cell carcinoma , consider noncandidate curative surgery . Nephrectomy mandatory . 5 . Patient renal cell carcinoma ( RCC ) clearcell histologic component confirm local pathology review . 6 . Females negative serum pregnancy test unless childbearing potential otherwise exclude 7 . Fertile woman childbearing potential ( &lt; 2 year last menstruation ) men must use effective mean contraception 8 . MemorialSloanKetteringCancerCentre favourable intermediate prognostic group . 9 . Measurable nonmeasurable disease ( per RECIST1.1 criterion ) 10 . Karnofsky Performance status 70 % high . 11 . Life expectancy great 4 month . 12 . The required laboratory value baseline follow : Haematology : WCC ≥ 3.0 x 109/L , Platelet count ≥ 100 x 109/L , Haemoglobin ≥ 6.2 mmol/l , ( INR ) ≤ 1.5 , APTT ≤ 1.5 x ULN Biochemistry : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , AST , ALT ≤ 2.5 x ULN patient without liver metastasis , ≤ 5 x ULN patient liver metastasis , Serum Creatinine ≤ 150 micromol/L 1 . Prior systemic treatment metastatic RCC disease 2 . Major surgical procedure , open surgical biopsy , significant traumatic injury within 28 day prior randomization . 3 . Serious nonhealing wound , ulcer bone fracture . 4 . Evidence current central nervous system ( CNS ) metastases spinal cord compression . Patient must undergo MRI CT scan brain ( contrast , possible ) within 28 day prior randomization . 5 . Seizure ( ) control standard medical therapy . 6 . Dipstick urine test protein ≥ 2+ . 7 . Other malignancy within 5 year prior randomization ( curatively treat basal cell carcinoma skin and/or situ carcinoma cervix ) . 8 . Evidence bleed diathesis coagulopathy . 9 . Ongoing recent ( within 10 day prior study treatment start ) need full therapeutic dose oral anticoagulant chronic daily treatment aspirin . Low molecular weight heparin allow 10 . Uncontrolled hypertension ( ≥ 160 mm Hg systolic and/or ≥ 100 mm Hg diastolic ) receive chronic medication . 11 . Clinically significant ( i.e . active ) cardiovascular disease , example cerebrovascular accident ( ≤ 6 month randomisation ) , myocardial infarction ( ≤ 6 month randomisation ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication . 12 . Recent ( within 30 day prior randomization ) treatment another investigational drug participation another investigational study . 13 . Chronic treatment corticosteroid ( dose ≥ 10 mg/day methylprednisolone equivalent ) , exclude inhaled steroid . 14 . History presence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug patient high risk treatment complication . 15 . Known hypersensitivity interleukin2 , Interferon , alfa bevacizumab . Serial blood test , serial tumor biopsy serial dynamic contrastenhanced image obtain part translational research program integrate clinical trial . Part ( ) translational research program may omit individual patient due practical , technical safety reason , without consequence participate additional translational research investigation clinical part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>interferon-alpha</keyword>
</DOC>